MJNA Medical Marijuana Inc

Medical Marijuana, Inc. Subsidiary Kannaway® Receives BSCG Certified Drug-Free Approval for Its Pure Gold CBD

Medical Marijuana, Inc. Subsidiary Kannaway® Receives BSCG Certified Drug-Free Approval for Its Pure Gold CBD

Pure Gold Recognized as Free of Substances Banned by US Anti-Doping Agency (USADA) and Professional Sports Leagues

SAN DIEGO, CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- via --  (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary  has received  approval from the Banned Substances Control Group (BSCG), a leading third-party certification and testing provider of dietary supplements and natural products, for its broad-spectrum cannabidiol (CBD) product . 

“As pioneers in the CBD industry, we were one of the first companies to conduct third-party testing on all of our products and provide those results to our customers,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “This certification furthers our dedication to providing athletes and general consumers alike the confidence to enjoy Pure Gold CBD without the fear of drug testing.”

BSCG is the standard in testing for third-party certification that ensures products meet quality specifications and are not contaminated with drugs or agents that can lead to health concerns or positive drug tests. 

The BSCG Certified Drug Free program requires companies to submit their products through a thorough toxicology review, ingredient evaluation, Good Manufacturing Practices (GMP) quality control process review, and continual random product testing. It provides protection against drugs on the World Anti-Doping Agency (WADA) Prohibited List as well as prescription over-the-counter (OTC) and illicit drugs not banned in sports.

“The greatest value that we can provide our customers with is trust and we aim to offer this time and time again by guaranteeing that our products are of the highest quality, safe, consistent, and accurately labeled,” said Kannaway® CEO Blake Schroeder. “We take every opportunity we are given to test and certify our products and hope that consumers see that as our commitment to them."

To learn more about BSCG or view Kannaway’s certification, please visit . 

About Kannaway®

 is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.

About Medical Marijuana, Inc.

. Medical Marijuana, Inc. () is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by  and ; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including  and  Medical Marijuana, Inc. was named a top CBD producer by . Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product  has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. 

Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at  or by visiting . To see Medical Marijuana, Inc.’s corporate video, .

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

LEGAL DISCLOSURE

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations Contact:

Kathryn Brown

Account Supervisor

CMW Media

P. 858-264-6600



Investor Relations Contact:

P. (858) 283-4016



EN
24/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medical Marijuana Inc

 PRESS RELEASE

Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on ...

Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on Profitability, Further Expansion World’s First-Ever Publicly Traded Cannabis Company Appoints Longtime Board Member as New CEO SAN DIEGO, CA , March 14, 2023 (GLOBE NEWSWIRE) -- via – (OTC: MJNA) (the “Company”), a holding company with operating assets dedicated to the cannabis and hemp industries, along with portfolio investments in companies in the biotechnology industry, announced today the appointment of Dr. Timothy R. Scott as its new Chief Executive Officer, President, and Chairman of the Board. Dr. Scott takes ...

 PRESS RELEASE

Medical Marijuana, Inc. Participates in Preclinical Research Study on ...

Medical Marijuana, Inc. Participates in Preclinical Research Study on Therapeutic Benefits of CBD on Traumatic Brain Injuries Study Carried Out by Center for Research and Advanced Studies of the IPN and the Siglo XXI National Medical Center Show Advantages of Oral Administration of CBD to Reduce Levels of Neuronal Death in Animal Model SAN DIEGO, CA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- via –  (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply c...

 PRESS RELEASE

Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Launches Two New F...

Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Launches Two New Full Spectrum Concentrations in Brazil With Competitive Price Point New Products Offer 3,000mg to 6,000mg, Will Come in Jars of 30 and 60mL, Presenting Significant Cost Savings to Rapidly Growing Brazil Market SAN DIEGO, CA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- via – (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary launched two new fu...

 PRESS RELEASE

Medical Marijuana, Inc. Subsidiary Kannaway Expands Leadership Team Wi...

Medical Marijuana, Inc. Subsidiary Kannaway Expands Leadership Team With Appointment of Industry Veterans to Roles of Executive Vice President and Vice President of Information Technology Direct Selling Subsidiary Taps Network Marketing Legends to Lead Communication and Information Technologies as Company Continues International Expansion SAN DIEGO, CA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via – (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply ch...

 PRESS RELEASE

Medical Marijuana, Inc. Reports $4.9 Million in Net Revenue in 2022 Th...

Medical Marijuana, Inc. Reports $4.9 Million in Net Revenue in 2022 Third Quarter Financial and Operational Results SAN DIEGO, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via – (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today its financial results for the quarter ending September 30, 2022, and provided an overview of recent operational highlights. First Quarter 2022 Financial and Operational Highlights Generated $4.9 million...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch